2'-deoxy-2'-C-α-methyluridine | 151384-13-3

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 2'-deoxy-2'-C-α-methyluridine
• 英文别名: 2'-deoxy-2'-α-methyluridine；1-((2R,3R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione；2'-Deoxy-2'-methyluridine；1-[(2R,3R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]pyrimidine-2,4-dione
• CAS: 151384-13-3
• 化学式: C₁₀H₁₄N₂O₅
• 分子量: 242.232
• InChiKey: HWYVSJPOGFIERF-MTSNSDSCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  99.1
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2'-deoxy-2'-C-α-methyluridine 在 吡啶 、 咪唑 、 4-二甲氨基吡啶 、 2,4,6-三异丙基苯磺酰氯 、 triethylamine trihydrofluoride 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 27.0h， 生成 5'-O-(dimethoxytrityl)-2'-deoxy-2'-α-methyl-N⁴-benzoylcytidine
  参考文献：
  名称：

  Synthesis of the Phosphoramidite Derivatives of 2‘-Deoxy-2‘-C-α-methylcytidine and 2‘-Deoxy-2‘-C-α-hydroxymethylcytidine:  Analogues for Chemical Dissection of RNA's 2‘-Hydroxyl Group

  摘要：

  Oligonucleotides containing 2'-C-alpha-methyl and 2'-C-alpha-hydroxymethyl modifications enable strategies for delineation of the distinctive role fulfilled by the 2'-hydroxyl group in RNA structure and function. Synthetic routes to the phosphoramidite derivatives of 2'-deoxy-2'-C-alpha-methylcytidine (14%, 15 steps) and 2'-deoxy-2'-C-alpha-hydroxymethylcytidine (19%, 10 steps) from methyl 3,5-di-O-(4-chlorobenzyl)-alpha-D-ribofuranoside are developed.

  DOI：

  10.1021/jo0495337
• 作为产物：
  描述：

  2′,3′,5′-tri-O-benzoyl-2′-C-methyluridine 在 咪唑 、 4-二甲氨基吡啶 、 偶氮二异丁腈 、 四丁基氟化铵 、 氨 、 三正丁基氢锡 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 、 甲苯 、 乙腈 为溶剂， 反应 54.0h， 生成 2'-deoxy-2'-C-α-methyluridine
  参考文献：
  名称：

  2′-脱氧-2′-C-β-甲基胞苷的亚磷酰胺衍生物的合成。

  摘要：

  2'-脱氧-2'-C-β-甲基核苷引起了人们对作为潜在治疗剂和类似物分析核酸结构和功能的兴趣。合成2'-脱氧-2'-C-甲基尿苷（11），2'-脱氧-2'-C-甲基胞苷（12）和2'-脱氧-2'-亚磷酰胺衍生物的有效途径描述了来自1,2,3,5-四-O-苯甲酰基-2-C-β-甲基核呋喃糖（1）的C-β-甲基胞苷（10，总产率46％）。

  DOI：

  10.1021/jo034263y

文献信息

• Azido nucleosides and nucleotide analogs
  申请人：Alios BioPharma, Inc.

  公开号：US09346848B2

  公开（公告）日：2016-05-24

  Disclosed herein are 4′-azido-substituted nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of 4′-azido-substituted nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a 4′-azido-substituted nucleoside, a nucleotide and/or an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection.

  本文披露了4'-偶氮基取代核苷、核苷酸及其类似物，包括其中一个或多个4'-偶氮基取代核苷、核苷酸及其类似物的药物组合物，以及它们的合成方法。本文还披露了使用4'-偶氮基取代核苷、核苷酸和/或其类似物来改善和/或治疗疾病和/或病况的方法，包括由副粘病毒和/或正粘病毒引起的感染。病毒感染的例子包括呼吸道合胞病毒（RSV）和流感感染。
• OLIGONUCLEOTIDE
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：US20150376611A1

  公开（公告）日：2015-12-31

  The present invention provides an oligonucleotide having improved affinity for AGO2, and the like. The oligonucleotide has a nucleotide residue or a nucleoside residue represented by formula (I) wherein X 1 is an oxygen atom or the like, R 1 is formula (IIA) (wherein R 5A is halogen or the like, and R 6A is a hydrogen atom or the like) or formula (IVA) (wherein Y 3A is a nitrogen atom or the like, and Y 4A is CH or the like), or the like, R 2 is a hydrogen atom, hydroxy, halogen, or optionally substituted lower alkoxy, and R 3 is a hydrogen atom or the like} at the 5′ end thereof, and the nucleotide residue or the nucleoside residue binds to an adjacent nucleotide residue through the oxygen atom at position 3.

  本发明提供了一种具有改善对AGO2亲和力的寡核苷酸等。该寡核苷酸在其5'端具有由式(I)表示的核苷酸残基或核苷酸残基其中X 1 是氧原子或类似物，R 1 是式(IIA)（其中R 5A 是卤素或类似物，而R 6A 是氢原子或类似物）或式(IVA)（其中Y 3A 是氮原子或类似物，而Y 4A 是CH或类似物），或类似物，R 2 是氢原子、羟基、卤素或可选择地取代的较低烷氧基，而R 3 是氢原子或类似物}，并且该核苷酸残基或核苷酸残基通过位于位置3的氧原子与相邻核苷酸残基结合。
• Process for the preparation of cytidine derivatives
  申请人：——

  公开号：US20030032797A1

  公开（公告）日：2003-02-13

  An efficient method for producing cytidine derivatives that took away the previous drawbacks by efficiently synthesizing cytidine derivatives by utilizing a tertiary amine can be provided.

  一种高效生产胞嘧啶衍生物的方法，通过利用三级胺有效地合成胞嘧啶衍生物，从而消除了先前的缺点。
• Sugar modified oligonucleotides
  申请人：ISIS Pharmaceuticals, Inc.

  公开号：US20030004325A1

  公开（公告）日：2003-01-02

  Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least one of the 2′-deoxyfuranosyl moieties of the nucleoside unit is modified. Treatment of diseases caused by various viruses and other causative agents is provided.

  提供了用于治疗和诊断可通过调节特定蛋白质产生的疾病的组合物和方法。根据优选实施例，提供了可以与RNA或DNA的选定序列特异性杂交的寡核苷酸和寡核苷酸类似物，其中核苷酸单元的至少一个2'-脱氧呋喃糖苷基被修改。提供了治疗由各种病毒和其他致病因素引起的疾病的方法。
• OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：US20170354673A1

  公开（公告）日：2017-12-14

  An oligonucleotide having a nucleotide residue or a nucleoside residue represented by formula (I) wherein X 1 is an oxygen atom or the like, R 1 is formula (IIA) (wherein R 5A is halogen or the like, and R 6A is a hydrogen atom or the like), formula (IVA) (wherein Y 3A is a nitrogen atom or the like, and Y 4A is CH or the like), or the like, R 2 is a hydrogen atom, hydroxy, halogen, or optionally substituted lower alkoxy, and R 3 is a hydrogen atom or the like, or formula (VI) (wherein n2 is 1, 2 or 3)} at the 5′ end thereof, wherein the nucleotide residue or the nucleoside residue binds to an adjacent nucleotide residue through the oxygen atom at position 3, is provided.

  具有由式(I)表示的核苷酸残基或核苷酸残基的寡核苷酸其中X1是氧原子或类似物，R1是式(IIA)（其中R5A是卤素或类似物，而R6A是氢原子或类似物），式(IVA)（其中Y3A是氮原子或类似物，而Y4A是CH或类似物），或类似物，R2是氢原子，羟基，卤素，或可选择地取代的较低烷氧基，而R3是氢原子或类似物，或式(VI)（其中n2为1、2或3）}在其5'端，其中核苷酸残基或核苷酸残基通过位于位置3的氧原子与相邻核苷酸残基结合。